Prediction: Pfizer Stock Could Double If Pipeline Delivers
Pfizer stock is navigating a pivot from COVID-era revenues to a broader drug portfolio. Analysts weigh the odds of a ...
This section highlights volatility metrics for the dividend aristocrats ETF, offering key indicators to monitor risk and potential entry points.
22,062 articlesPfizer stock is navigating a pivot from COVID-era revenues to a broader drug portfolio. Analysts weigh the odds of a ...
As global tensions persist, defense giants report robust backlogs that signal predictable revenue. Here are three hig...
Imagine the next 10 years of your portfolio. This piece explains why Costco's shine may not translate into a top inve...
As Johnson & Johnson prepares July earnings, investors weigh the real case buying johnson thesis driven by durable in...
You don't need a fortune to follow Warren Buffett's philosophy. With $300, you can start a durable, moat-rich lineup ...
GSK has seen a steep run in its stock, prompting questions about whether the rally still offers upside. This article ...
Berkshire Hathaway disclosed a new stake in Macy’s in its Q1 2026 13F, a small starter position that contrasts with p...
A blockbuster year for Delek US Holdings brought attention to a notable insider move. The event described as delek in...
Investors are watching whispers about Apple and Intel teaming up. This article breaks down what that could mean for s...
Want money that grows without constant effort? This guide reveals the top apps that help you earn passive income, how...
Abbott Laboratories and Pfizer both delivered solid Q1 2026 numbers, yet the market sentiment diverged. Abbott slumpe...
Pitney Bowes is navigating a pivot from legacy mailing services to software, data, and commerce solutions. This break...